NeuroSense Therapeutics (NASDAQ: NRSN) reported a net loss of $3.56 million for the first half of 2026, a decrease from $4.71 million in the same period last year. The late-stage biotechnology company also outlined plans to submit a New Drug Submission (NDS) for its ALS treatment, PrimeC, in Canada by December 2026.

The reduction in losses was driven by a 26.5% decline in total operating expenses, which fell to $3.45 million from $4.69 million in H1 2025. Research and development expenses decreased 16% to $2.10 million, primarily due to lower subcontractor and consultant costs, partially offset by higher share-based payment expenses. General and administrative expenses dropped 38.6% to $1.35 million, reflecting reduced professional service fees.

Regulatory and Clinical Milestones

NeuroSense is advancing PrimeC through regulatory pathways in the United States and Canada. Key developments include:

• Canadian NDS Filing: Following a Pre-NDS meeting with Health Canada, the company is preparing an NDS for PrimeC in ALS, targeting submission in December 2026. Health Canada indicated no concerns with the proposed timeline.
• U.S. Development Strategy: The company is pursuing an optimized path including AI-enabled characterization and a planned active-comparator study against edaravone. It aims to discuss Accelerated Approval or full approval pathways with the FDA.
• Clinical Data Validation: In March 2026, Phase 2b PARADIGM study results were published in JAMA Neurology. Long-term follow-up data showed a statistically significant 65% reduction in the risk of death for participants treated continuously with PrimeC compared to those initially assigned to placebo.

Financial Performance Overview

The following table summarizes NeuroSense's financial results for the six months ended June 30, 2026, compared to the prior year period.

What the Numbers Show

A divergence exists between the company's cash position and its near-term liabilities. As of June 30, 2026, NeuroSense held $231 thousand in cash and cash equivalents against total current liabilities of $2.999 million. This significant gap underscores the critical importance of the financing initiatives mentioned in the update, as the company continues to pursue non-dilutive funding and strategic alternatives to support the capital-intensive next stages of clinical development and regulatory submissions.

Corporate Highlights

Beyond financials, NeuroSense strengthened its intellectual property portfolio during the first half of 2026. The company secured a U.S. patent covering the use of PrimeC through 2043 and expanded composition patent protection through 2042 in Australia, Brazil, Japan, and South Korea. Additionally, Prof. Steven E. Arnold joined the Scientific Advisory Board to support the Alzheimer’s program, which reported positive biomarker findings in the Phase 2 RoAD proof-of-concept study.

NeuroSense Therapeutics announced a 1-for-20 reverse stock split, scheduled to take effect on September 14. The corporate action will reduce the number of outstanding shares while proportionally increasing the per-share price.

The company filed the details with the US Securities and Exchange Commission (SEC). The split is designed to adjust the company's capital structure metrics without changing the total market value of shareholders' investments.

Corporate Action Details

Shareholders holding shares prior to the effective date will see their holdings adjusted according to the specified ratio. Fractional shares resulting from the calculation will typically be settled in cash or rounded up, depending on the company's specific settlement policy as outlined in its official filings.